Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); 2012 Preview: Cautious in Front of Pimavanserin Phase 3 Results Expected in 3Q12
ACAD Hot Sheet
Rating Summary:1 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Needham & Company maintains a 'Hold' on Acadia Pharmaceuticals (NASDAQ: ACAD).
Needham analyst says, "ACADIA plans to announce results from its third Phase 3 trial of pimavanserin in Parkinson’s disease psychosis (PDP; Study 020) around 3Q12. We remain cautious due to disappointing results from two previous Phase 3 trials in this indication. Based on a retrospective analysis of data, management believes that certain changes in trial design could lead to a positive outcome. However, insufficient data from these analyses have been disclosed for us to fully assess whether changes applied to Study 020 will have a favorable impact on outcome."
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $1.10 yesterday, with a 52 week range of $0.90-$3.30.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Needham analyst says, "ACADIA plans to announce results from its third Phase 3 trial of pimavanserin in Parkinson’s disease psychosis (PDP; Study 020) around 3Q12. We remain cautious due to disappointing results from two previous Phase 3 trials in this indication. Based on a retrospective analysis of data, management believes that certain changes in trial design could lead to a positive outcome. However, insufficient data from these analyses have been disclosed for us to fully assess whether changes applied to Study 020 will have a favorable impact on outcome."
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $1.10 yesterday, with a 52 week range of $0.90-$3.30.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UBS Maintains a 'Buy' on Ralph Lauren (RL); Taking A More Conservative Approach
- Goldman Sachs Keeps Top Rating on Ralph Lauren (RL) After Q4 Results, Says Buy Pullback
- UBS Raises Price Target and Estimates on PetSmart (PETM); Sees Sustained Sales and Margin Benefit
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
